 |
|
|
|
|
|
 Title: |
US6265541:
Uses of α-conotoxin peptides
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Olivera, Baldomero M.; Salt Lake City, UT
McIntosh, J. Michael; Salt Lake City, UT
Yoshikami, Doju; Salt Lake City, UT
Cartier, G. Edward; Salt Lake City, UT
Luo, Siqin; Salt Lake City, UT
|
| Assignee: |
University of Utah Research Foundation, Salt Lake City, UT
other patents from UNIVERSITY OF UTAH RESEARCH FOUNDATION (600050) (approx. 286)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
2001-07-24
/ 1998-12-23
|
| Application Number: |
US1998000219446
|
| IPC Code: |
Advanced:
A61K 38/08;
A61K 38/17;
C07K 14/435;
C12N 15/12;
Core:
more...
IPC-7:
A61K 38/00;
C07K 14/00;
C07K 14/435;
C12N 15/12;
|
| ECLA Code: |
A61K38/17;
|
| U.S. Class: |
Current:
530/326;
530/300;
530/324;
Original:
530/326;
530/326;
530/300;
530/324;
514/012;
514/013;
514/002;
|
| Field of Search: |
530/326,324,300
514/002,12,13
|
| Government Interest: |
This invention was made with Government support under Grant Nos. GM48677 and MH53631 awarded by the National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.
|
| Priority Number: |
| 1998-12-23 |
US1998000219446 |
| 1997-12-31 |
US1997000070153P |
| 1998-04-03 |
US1998000080588P |
|
| Abstract: |
The present invention relates to the use of alpha-conotoxin peptides having the general formulafor treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma. In this formula, Xaa1 is des-Xaa1, Tyr, mono-iodo-Tyr or di-iodo-Tyr, Xaa2 is any amino acid, Xaa3 is any amino acid, Xaa4 is any amino acid, Xaa5 is any amino acid and Xaa6 represents a peptide of 3-7 amino acids. Disulfide linkages exist between the first and third cysteines and the second and fourth cysteines. Pro may be replaced with hydroxy-Pro. The C-terminus may contain a hydroxyl or an amide group, preferably an amide group.
|
| Attorney, Agent or Firm: |
Rothwell, Figg, Ernst & Manbeck, pc ;
|
| Primary / Asst. Examiners: |
Carlson, Karen Cochrane; Robinson, Patricia
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
| Parent Case: |
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is related to U.S. provisional patent application No. 60/070,153, filed Dec. 31, 1997 and to U.S. provisional patent application No. 60/080,588, filed Apr. 3, 1998, each incorporated herein by reference.
|
| Designated Country: |
AL AM AP AT AZ BA BB BG BR BY CA CH CN CU CZ DE DK EA EE EP ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
|
| Family: |
Show 5 known family members
|
First Claim:
Show all 19 claims |
What is claimed is:
1. A substantially pure α-conotoxin peptide selected from the group consisting of:
- Gly-Cys-Cys-Ser-Leu-Pro-Pro-Cys-Ala-Leu-Asn-Asn-Pro-Asp-Tyr-Cys (SEQ ID NO:10);
- Gly-Cys-Cys-Ser-Leu-Pro-Pro-Cys-Ala-Ala-Ser-Asn-Pro-Asp-Tyr-Cys (SEQ ID NO:11);
- Tyr-Gly-Cys-Cys-Ser-Asn-Pro-Val-Cys-His-Leu-Glu-His-Ser-Asn-Leu-Cys (SEQ ID NO:3); and
- Gly-Cys-Cys-Ser-Asn-Pro-Val-Cys-Phe-Ala-Thr-His-Ser-Asn-Leu-Cys (SEQ ID NO:4).
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 1 U.S. patent(s) that reference this one
|
|
